In addition, DNA vaccination with the Her2 antigen prior to Her2+ tumor challenge induced a robust anti-tumor response, with up to 33% survival of Her2+ mice (compared to 0% survival in Her2+ unvaccinated mice), indicating these mice were able to overcome tolerance to the Her2 antigen, and successfully mount an immune response. The gene discussed is ERBB2; the disease is neoplasm.